Free tool
FAERS Monitor: Evenity
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761062 or its brand name (Evenity, Romosozumab-Aqqg). Reports on generic versions are filed under their own applications.
Reports
14,247
Serious
8,363
59% of reports
Hospitalization
3,477
Death reported
759
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fall844
- fracture676
- arthralgia670
- injection site pain592
- off label use528
- headache498
- hospitalisation481
- bone density abnormal463
- product storage error357
- pain344
- pain in extremity340
- spinal fracture335
- death333
- femur fracture314
- injection site swelling312
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 776 |
| 2020 | 1,210 |
| 2021 | 1,454 |
| 2022 | 2,389 |
| 2023 | 2,110 |
| 2024 | 2,143 |
| 2025 | 2,097 |
| 2026 | 2,067 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,912 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bone density abnormalSignal | 463 | 208.6 | 189.5 | 83,648 |
| fractureSignal | 676 | 54.6 | 50.7 | 34,307 |
| spinal fractureSignal | 335 | 25.1 | 22.5 | 7,599 |
| femur fractureSignal | 314 | 15.1 | 13.5 | 4,088 |
| product storage errorSignal | 357 | 6.0 | 5.5 | 1,497 |
| injection site swellingSignal | 312 | 6.0 | 5.4 | 1,304 |
| hospitalisationSignal | 481 | 4.6 | 4.2 | 1,372 |
| fallSignal | 844 | 3.8 | 3.5 | 1,723 |
| injection site painSignal | 592 | 2.9 | 2.6 | 720 |
| arthralgiaSignal | 670 | 2.4 | 2.2 | 545 |
| pain in extremity | 340 | 1.7 | 1.5 | 100 |
| headache | 498 | 1.2 | 1.1 | 13 |
| off label use | 528 | 0.9 | 0.8 | 7 |
| pain | 344 | 0.8 | 0.7 | 13 |
| death | 333 | 0.6 | 0.5 | 112 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.